Clinical trial
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients…
NCT00004039 · Hoag Memorial Hospital Presbyterian, Other · Withdrawn
Key facts
| NCT number | NCT00004039 |
|---|---|
| Title | Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma |
| Official title | Phase II Trials of CHOP Chemotherapy and Interferon Alpha or Rituximab Anti-CD20 Monoclonal Antibody as Initial Treatment of Patients With Stage III and IV High-Risk Indolent B-Cell Lymphoma and Intermediate Grade B-Cell Lymphoma |
| Lead sponsor | Hoag Memorial Hospital Presbyterian, Other |
| Collaborators | Cancer Biotherapy Research Group |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | recombinant interferon alfa, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate |
| Enrollment | 0 |
| Start date | Jun 1, 1998 |
| Primary completion | Jan 1, 2000 |
| Completion | Jan 1, 2000 |
| First posted | Aug 5, 2004 |
| Last update posted | Aug 19, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: